迈瑞医疗74岁董事长李西廷2亿元增持完毕，去年领薪近2500万元

Core Viewpoint - Mindray Medical (SZ300760) announced the completion of a share buyback plan by its chairman, Li Xiting, who invested 200 million yuan in the company, reflecting confidence in its intrinsic value and future development [1][2]. Group 1: Share Buyback Details - Li Xiting's share buyback plan was initiated on November 27, 2025, and completed ahead of schedule by December 12, 2025, during which he acquired 1,005,381 shares, representing 0.08% of the company's total shares [1]. - The total investment for the buyback was 200 million yuan, including transaction fees, and there is a lock-up period of six months following the completion of the buyback [1]. Group 2: Shareholding Structure - Prior to the buyback, Li Xiting did not hold shares directly but controlled 327,072,335 shares (26.98%) indirectly through Smartco Development Limited, while his associate Xu Hang controlled 296,951,000 shares (24.49%) through Magnifice (HK) Limited [2]. - After the buyback, Li Xiting directly holds 1,005,381 shares, while the indirect holdings of Smartco Development and Magnifice (HK) remain unchanged, resulting in a total control of 625,028,716 shares (51.55%) by Li Xiting and his associates [2]. Group 3: Financial Performance - Mindray Medical reported a decline in both revenue and profit for the first three quarters of 2025, with total revenue of 25.834 billion yuan, a year-on-year decrease of 12.38%, and a net profit of 7.570 billion yuan, down 28.83% [4]. - The basic earnings per share for the same period were reported at 6.25 yuan [4]. Group 4: Company Background - Mindray Medical, established on January 25, 1999, is located in Shenzhen, Guangdong Province, and specializes in the research, manufacturing, marketing, and service of medical devices [5].